Sort
27,075 grants matching “cholesterol”
Targeting of Voltage-gated K+ Channels to Lipid Rafts
$380,605Colorado State University-Fort Collins · R01 · FY2001 · NS
Iron Therapy in Renal Disease: Potential Toxicities
$380,600Fred Hutchinson Cancer Research Center · R01 · FY2005 · DK
Iron Therapy in Renal Disease: Potential Toxicities
$380,600Fred Hutchinson Cancer Research Center · R01 · FY2004 · DK
ARCH PLAQUES AND STROKE IN AN ETHNICALLY MIXED COMMUNITY
$380,585Columbia University Health Sciences · R01 · FY2001 · NS
Diacylglycerol Lactones as C1 Ligands for Protein Kinase C and Related Proteins
$380,577Victor Marquez · Division Of Basic Sciences - Nci · Z01 · FY2008 · CA
RNA-binding proteins in atherosclerosis
$380,529Tamer Sallam · University Of California Los Angeles · R01 · FY2021 · HL
RNA-binding proteins in atherosclerosis
$380,491Tamer Sallam · University Of California Los Angeles · R01 · FY2018 · HL
HDL and cardiovascular risk in chronic kidney disease
$380,456Andrew N Hoofnagle · University Of Washington · R01 · FY2015 · HL
VEGF-C/VEGFR3 AND LYMPHATIC TRANSPORT OF CHOLESTEROL FROM ATHEROSCLEROTIC PLAQUE
$380,440Gwendalyn J Randolph · Washington University · R01 · FY2016 · HL
VEGF-C/VEGFR3 AND LYMPHATIC TRANSPORT OF CHOLESTEROL FROM ATHEROSCLEROTIC PLAQUE
$380,440Gwendalyn J Randolph · Washington University · R01 · FY2017 · HL
Financial Incentives to Translate ALLHAT into Practice
$380,407Laura A Petersen · Baylor College Of Medicine · R01 · FY2011 · HL
High Intensity Body-weight Circuit Training Feasibility and Efficacy for Improving Metabolic Profile, Body Composition, and Health-Related Fitness in Middle Aged Persons with Type 2 Diabetes
$380,405Brian Kliszczewicz · Kennesaw State University · R15 · FY2021 · AG
RNA-binding proteins in atherosclerosis
$380,340Tamer Sallam · University Of California Los Angeles · R01 · FY2022 · HL
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
$380,328Genhong Cheng · University Of California Los Angeles · R01 · FY2022 · AI
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
$380,328Michael E Jung · University Of California Los Angeles · R01 · FY2025 · AI
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
$380,328Michael E Jung · University Of California Los Angeles · R01 · FY2023 · AI
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
$380,328Genhong Cheng · University Of California Los Angeles · R01 · FY2021 · AI
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
$380,328Genhong Cheng · University Of California Los Angeles · R01 · FY2020 · AI
Reversal of preexisting neuropathic pain by spinal delivery of AIBP
$380,298Yury Miller · University Of California, San Diego · R21 · FY2018 · NS
Functional studies of KLF14, a putative master regulator of metabolism
$380,250Kiran Musunuru · Harvard University · R01 · FY2015 · DK
Intracerebroventricular cyclodextrin and AAV-mediated gene therapy forglobal CNS disease correction in feline NPC1 disease
$380,230Charles H Vite · University Of Florida · R01 · FY2025 · NS
Impact of dyslipidemia on endothelial biomechanics
$380,220Irena Levitan · University Of Illinois At Chicago · R01 · FY2010 · HL
Sphingosine-1-phosphate Signaling and the Chronic Glucocorticoid Exposure Induced Glucose Homeostasis Disorder
$380,211Jen-Chywan Wang · University Of California Berkeley · R01 · FY2024 · DK
Juvenile Protective Factors and Their Effects on Aging
$380,192Shumei S Sun · Virginia Commonwealth University · R01 · FY2016 · AG
Functional Microdomains in the Heart's Pacemaker: A New Dimension of Cardiac Remodeling
$380,164Alexey V Glukhov · University Of Wisconsin-Madison · R01 · FY2022 · HL